Acute Lymphoblastic Leukaemias (ALL) Completed Phase 4 Trials for Cyclophosphamide (DB00531)

Also known as: Acute Lymphoblastic Leukemias / Acute Leukemia, Lymphoblastic / Acute Lymphoblastic Leukaemia / Acute Lymphoblastic Leukemia / Leukemia, Lymphoblastic, Acute / Lymphoblastic Leukemia, Acute / Leukemia, Acute Lymphoblastic / Leukaemia, Lymphoblastic, Acute / Acute Lymphoblastic Leukemia (ALL) / Leukemia, Lymphoblastic,Acute / Acute Leukaemia, Lymphoblastic / Acute lymphoblastic leukemia with failed remission / Leukemia lymphoblastic acute / Lymphoid leukaemia, acute / Acute lymphoid leukaemia / Lymphoid leukemia, acute / Acute lymphoid leukemia / ALL / Leukaemia lymphoblastic acute / Acute lymphocytic leukemia / Acute lymphatic leukaemia / Leukaemias acute lymphocytic / Acute lymphatic leukemia / Acute lymphocytic leukaemia

IndicationStatusPhase
DBCOND0073466 (Acute Lymphoblastic Leukaemias (ALL))Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00494897PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic LeukemiaTreatment
NCT00526409LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic LeukemiaTreatment
NCT00526305LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia PositiveTreatment
NCT00526175LAL-BR/2001: Study Treatment to Low Risk ALLTreatment
NCT01358253Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic LeukemiaTreatment